Use of spinosyns and spinosyn compositions against herpesviridae viral infections
View Patent ↗The present invention relates to the use of spinosyns and spinosyn compositions as pharmaceuticals and methods for treatment—including prevention—of protozoan infections and/or disorders relating to a protozoan infection, such as malaria and leishmania , viral infections such as Herpes Simplex virus and Influenza virus and neoplastic disorders or cancer. Advantageously, compositions of the invention inhibit protozoan, virus growth and neoplastic cell proliferation with only minimal or no disruption or harm to the host which may be an animal or human.
1. A method of treating a host suffering from a viral infection caused by a virus belonging to the family of Herpesviridae, comprising administering to said host a therapeutically effective amount of a composition comprising at least one spinosyn or salt thereof and a suitable carrier.
2. The method of claim 1 , wherein the virus is selected from at least one or more serotypes and subtypes of the Herpes Simplex Virus 1 (HSV1), Herpes Simplex Virus 2 (HSV2), and varicella-zoster virus.
3. The method of claim 1 , wherein the spinosyn is chosen from at least one or more of spinosyn A, spinosyn D, spinosad, or spinetoram.
4. The method of claim 1 , wherein the spinosyn is chosen from at least one or both of spinosyn A and spinosyn D.
5. The method of claim 1 , wherein the spinosyn is administered to the host in a dose of 0.05 μg/kg body weight daily to 2000 mg/kg body weight daily, once or in multiple doses or by continuous infusion.
6. The method of claim 1 , wherein the spinosyn is administered to the host in a dose of 5 mg/kg body weight daily to 200 mg/kg body weight daily, once or in multiple doses or by continuous infusion.
7. The method of claim 1 , wherein at least one additional active agent is administered to the host simultaneously, separately or sequentially.
8. The method of claim 7 , wherein the at least one additional agent is chosen from one or more of an antiprotozoan, another antiviral, an anticancer agent, a biocide, an enzyme inhibitor, an antimetabolite, a vinca alkaloid, an alkylating agent, a polypeptide, an antibody, a vitamin, an immunostimulant, an interferon, a cytokine, an antibacterial agent, an antinematode, an anticestode, and an antitrematode agent contained in the same spinosyn composition or in different compositions.
9. The method of claim 1 , wherein the host is a human.
10. The method of claim 1 , wherein the host is an animal.
11. The method of claim 1 , wherein the spinosyn composition is administered simultaneously, separately or sequentially with one or more of Acyclovir, Cidofovir, Cytarabine, Dideoxyadenosine, Didanosine, Edoxudine, Famciclovir, Floxuridine, Inosine Pranobex, Lamivudine, MADU, Penciclovir, Sorivudine, Stavudine, Trifluridine, Valacyclovir, Vidarabine, Zalcitabine, Zidovudine,Zanamivir, Amantadine, Zidovudine (ATZ), Delavirdine, Indinavir, Interferon-α, Interferon-β, Interferon-γ, Kethoxal, Methisazone, Moroxydine, Nevirapine, Oseltamivir, Pleconaril, Podophyllotoxin, Rifampicin, Ribavirin, Rimantadine, Ritonavir, Saquinavir contained in the same spinosyn composition or in different compositions.
12. The method of claim 1 , wherein the composition is administered to the host enterally, parenterally, or topically.
13. The method according to claim 1 , wherein said administering is repeated periodically.
14. The method of claim 1 , wherein the composition comprising at least one spinosyn or salt thereof is administered to the host topically in a dose of 0.05 μg/cm 2 to 50 mg/cm 2 .
15. The method of claim 1 , wherein the composition is in the form of one or more of a solution, dispersion, suspension, emulsion, solution or powder for injection, patch, implantable delivery system, aerosol, capsule, tablet, pill, lozenge, hydrogel, cream, colloidal dispersion system, nanoparticle or liposome.